Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
about
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for induction of remission in ulcerative colitisOral 5-aminosalicylic acid for maintenance of remission in ulcerative colitisTraditional corticosteroids for induction of remission in Crohn's diseaseNovel Metal Nanomaterials and Their Catalytic ApplicationsMesalamine in the treatment and maintenance of remission of ulcerative colitisTetrahydrobiopterin biosynthesis as an off-target of sulfa drugsSearching for the delta: 5-aminosalicylic Acid therapy for Crohn's diseaseA retrospective analysis of 20-year data of the surgical management of ulcerative colitis patients in Taiwan: a study of Taiwan Society of Inflammatory Bowel Disease.Comparison of the effect of mesalazine and sulfasalazine on laboratory parameters: a retrospective observational study.Current approaches to the management of new-onset ulcerative colitis.Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?European evidence-based Consensus on the management of ulcerative colitis: Current management.Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.A new look at a mainstay ulcerative colitis therapyThe effect of gut microbiota on drug metabolism.Current therapy of ulcerative colitis in children.Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.Balsalazide Potentiates Parthenolide-Mediated Inhibition of Nuclear Factor-κB Signaling in HCT116 Human Colorectal Cancer Cells.Guidelines for the management of inflammatory bowel disease in adults.Review article: aminosalicylates in inflammatory bowel disease.Mesalazine for diverticular disease of the colon--a new role for an old drug.Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory ActivityUpdate on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management.Optimizing therapy in patients with pancolitis.Novel drug delivery strategies for the treatment of inflammatory bowel disease.Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis.Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisMMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.Red-Brown Urine Discolouration in Two Patients Taking Mesalamine.Renal effects of long-term treatment with 5-aminosalicylic acidBalsalazide disodium for the treatment of ulcerative colitis.
P2860
Q24185774-7B2D70F0-3619-4177-A3FB-AF7E4E277055Q24185876-79B4227B-F3F0-4AE9-B92E-299E1F79A7C3Q24198024-5F013556-F73E-4CC2-9ED5-A51F5FDD5C5AQ24198786-74E5FC3A-0CC6-4F47-A945-C8C34C0411DDQ24242955-C680F86E-4555-4EEB-ADBA-C724582541FFQ26782400-E671A829-5841-4308-BFA0-B6A024192401Q26865546-01CDEAC8-92A8-4EEE-9C93-7FEC39B4DB91Q27684698-A0470217-AA6D-4D1D-A592-9F7D58186739Q28390019-7FF61D8F-B812-4414-86A2-D8EEA984AF9DQ31115745-6EAC71D3-8099-42D2-91A7-BB8E17A896F6Q33401006-1742D888-D45A-4664-9647-4FD0AA0FE9C3Q33633288-47871567-CE2B-43FD-AB32-07EB1BC30D7DQ33868970-435743EC-6185-458F-A1EF-BF1214AF5E2BQ34025054-CE25D157-8051-48F6-AB33-943FE7620C3FQ34112953-E3DB190B-7844-4719-88E0-BB7B418DFC96Q34182017-41FA5969-3667-48C3-92FB-347686EBEC7DQ34273329-B494F90E-B62B-4DDA-9547-5CF81AFB895BQ34836490-97573858-311A-42CD-9DA6-1E7F4409F7F4Q34940520-13490238-BA5D-4375-BBA5-71BFE235911CQ34986604-6613195B-AD99-4E43-A36D-AACF4257EEAFQ35609674-1E6DDEC5-F8D6-4431-8255-FCFC8222DBDFQ35670802-05BA83BC-74FE-436C-9B99-1984727DFE33Q35777871-CB7CE7FE-6146-4280-A0B1-7EE081348EEBQ35790559-1D1B2F5D-DA60-45AC-A72E-17EDF265CFA9Q35880396-6236915E-4ED6-422A-A21A-30A6404C9DAEQ36040685-F153BFCA-1582-43D6-8E84-C68EB9DCCD8EQ36084796-283FA300-F563-4652-9A41-E70CAA2C84E3Q36144377-D7BC1888-E3A0-4381-A5DE-8739DC796FABQ36171739-3C177CD4-E189-4A20-A664-9498C1C52ED6Q36270395-E9F8A2DC-BF67-4A32-9C82-2CDF19FBDA36Q36316765-B2E86394-B62A-4D0A-9939-6CB53D3EF39BQ36555966-D8B51E6F-33A2-471B-8509-4491F0F6355AQ36589413-14DFAC63-03BA-4CB2-90F2-73BF233C27D1Q37101734-71090D99-9566-4D75-A989-FA6AD9E10457Q37123430-E99EDEA6-C719-4E8D-8511-50D7DFAB4CCBQ37135355-1D793EC9-C753-44F6-977F-F451623D25B1Q37162453-43222DE0-A45A-40D1-903F-4F33C2926B6EQ37219195-567E2A04-B39B-4256-86FC-C6428DFF04F1Q37223156-8577AC2C-C475-4180-B288-D6EBC3C53E0CQ37345858-2B815BEF-9B0E-4607-8959-CA82665ED7D7
P2860
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Systematic review: the pharmac ...... agement of ulcerative colitis.
@ast
Systematic review: the pharmac ...... agement of ulcerative colitis.
@en
Systematic review: the pharmac ...... agement of ulcerative colitis.
@nl
type
label
Systematic review: the pharmac ...... agement of ulcerative colitis.
@ast
Systematic review: the pharmac ...... agement of ulcerative colitis.
@en
Systematic review: the pharmac ...... agement of ulcerative colitis.
@nl
prefLabel
Systematic review: the pharmac ...... agement of ulcerative colitis.
@ast
Systematic review: the pharmac ...... agement of ulcerative colitis.
@en
Systematic review: the pharmac ...... agement of ulcerative colitis.
@nl
P2860
P1476
Systematic review: the pharmac ...... agement of ulcerative colitis.
@en
P2093
Hanauer SB
Sandborn WJ
P2860
P356
10.1046/J.1365-2036.2003.01408.X
P407
P577
2003-01-01T00:00:00Z